Legal & General Group PLC Bicycle Therapeutics PLC Transaction History

Legal & General Group PLC

$423 Billion
Q1 2024

A detailed history of Legal & General Group PLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Legal & General Group PLC holds 133,068 shares of BCYC stock, worth $2.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

133,068

Previous 133,068 -0.0%

Holding current value

$2.64 Million

Previous $3.31 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$16.75 - $26.1 $4,405 - $6,864	263 Added 0.2%	133,068 $3.31 Million
Q4 2023 Feb 15, 2024	BUY	$13.29 - $22.2 $536,145 - $895,592	40,342 Added 43.63%	132,805 $2.4 Million
Q3 2023 Nov 14, 2023	BUY	$19.9 - $26.25 $242,919 - $320,433	12,207 Added 15.21%	92,463 $1.86 Million
Q2 2023 Aug 14, 2023	BUY	$18.95 - $28.67 $1.27 Million - $1.92 Million	67,097 Added 509.89%	80,256 $2.05 Million
Q1 2023 May 15, 2023	BUY	$20.02 - $31.37 $52,572 - $82,377	2,626 Added 24.93%	13,159 $279,000

Q4 2022 Feb 14, 2023	BUY	$20.37 - $32.9 $28,518 - $46,060	1,400 Added 15.33%	10,533 $311,000
Q2 2022 Aug 22, 2022	SELL	$12.95 - $46.99 $27,622 - $100,229	-2,133 Reduced 18.93%	9,133 $154,000
Q1 2022 May 16, 2022	BUY	$40.12 - $59.5 $48,384 - $71,757	1,206 Added 11.99%	11,266 $495,000
Q4 2021 Feb 14, 2022	SELL	$41.7 - $61.14 $6,171 - $9,048	-148 Reduced 1.45%	10,060 $612,000
Q3 2021 Nov 15, 2021	BUY	$27.95 - $44.24 $60,847 - $96,310	2,177 Added 27.11%	10,208 $423,000
Q2 2021 Aug 12, 2021	BUY	$27.0 - $32.28 $216,837 - $259,240	8,031 New	8,031 $244,000

Others Institutions Holding BCYC

# of Institutions

Shares Held

30.6M

Call Options Held

85.5K

Put Options Held

11.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $588M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Bicycle Therapeutics PLC Transaction History